{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:22:23Z","timestamp":1790778143788,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.arr.2023.101996","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T21:15:41Z","timestamp":1688505341000},"page":"101996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Passive Alzheimer\u2019s immunotherapy: A promising or uncertain option?"],"prefix":"10.1016","volume":"90","author":[{"given":"Poul F.","family":"H\u00f8ilund-Carlsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper P.","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano L.","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos K.","family":"Robakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Vissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2023.101996_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11307-017-1146-y","article-title":"Correction for partial volume effect is a must, not a luxury, to fully exploit the potential of quantitative PET imaging in clinical oncology","volume":"20","author":"Alavi","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.arr.2023.101996_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00259-019-04564-5","article-title":"Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer's disease: why it is time to abandon the approach","volume":"47","author":"Alavi","year":"2020","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.arr.2023.101996_bib3","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2023.101996_bib4","article-title":"Crenezumab secondaries negative; gantenerumab OLE hints at efficacy","author":"Alzforum","year":"2022","journal-title":"Crenezumab Second. Negat. ; Gantenerumab OLE Hints Effic. | ALZFORUM"},{"key":"10.1016\/j.arr.2023.101996_bib5","article-title":"Response to van Dyck, O'Dell, & Mecca letter to the editor regarding Andrews et al. (2019)","volume":"9","author":"Andrews","year":"2023","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.101996_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.101996_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cercor\/1.1.103","article-title":"The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease","volume":"1","author":"Arnold","year":"1991","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.arr.2023.101996_bib8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3233\/JAD-230040","article-title":"Playing Russian Roulette with Alzheimer\u2019s disease patients: do the cognitive benefits of lecanemab outweigh the risk of edema, stroke and encephalitis?","volume":"92","author":"Atwood","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib9","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/ene.15007","article-title":"Brain volume loss due to donanemab","volume":"28","author":"Ayton","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2023.101996_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001191.pub3","article-title":"Rivastigmine for Alzheimer's disease","volume":"4","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.arr.2023.101996_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ana.25123","article-title":"Person-specific contribution of neuropathologies to cognitive loss in old age","volume":"83","author":"Boyle","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2023.101996_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.arr.2023.101996_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-221305","article-title":"Neuropathology of anti-amyloid-\u03b2 immunotherapy: a case report","volume":"93","author":"Castellani","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib14","article-title":"Conventional versus new treatment: comparing the effects of acetylcholinesterase inhibitors and n-methyl-d-aspartate receptor antagonist with aducanumab","volume":"14","author":"Chin","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.arr.2023.101996_bib15","unstructured":"Cision PR Newswire. 2023. Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease [Oline]. Published 3 May 2023. Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease (prnewswire.com). [Accessed 05.06.2023 2023]."},{"key":"10.1016\/j.arr.2023.101996_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3233\/JAD-220942","article-title":"Retrospective bayesian evidence of null effect in two decades of Alzheimer\u2019s disease clinical trials","volume":"91","author":"Costa","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib17","first-page":"1460","article-title":"Alzheimer\u2019s disease cooperative study data analysis and publication committee","volume":"370","author":"Doody","year":"2014","journal-title":"Phase 3 Trials solanezumab bapineuzumab Alzheimer'S. Dis."},{"key":"10.1016\/j.arr.2023.101996_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.101996_bib19","unstructured":"Eli Lilly and Company. 2023. Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease [Online]. Cision. Updated 8 March 2023. https:\/\/www.prnewswire.com\/news-releases\/lilly-provides-update-on-a4-study-of-solanezumab-for-preclinical-alzheimers-disease-301766069.html (Accessed 5 March 2023)."},{"key":"10.1016\/j.arr.2023.101996_bib20","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2023.101996_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcp.2013.11.009","article-title":"Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020","volume":"88","author":"Hampel","year":"2014","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.arr.2023.101996_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.arr.2023.101996_bib23","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3233\/JAD-215275","article-title":"Aducanumab (Marketed as Aduhelm) approval is likely based on misinterpretation of PET imaging data","volume":"84","author":"H\u00f8ilund-Carlsen","year":"2021","journal-title":"J. Alzheimers"},{"key":"10.1016\/j.arr.2023.101996_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3233\/JAD-220841","article-title":"Amyloid PET: a questionable single primary surrogate efficacy measure on Alzheimer immunotherapy","volume":"90","author":"H\u00f8ilund-Carlsen","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"Pt 1","key":"10.1016\/j.arr.2023.101996_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/brain\/awq349","article-title":"Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease","volume":"134","author":"Kadir","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.101996_bib27","doi-asserted-by":"crossref","first-page":"8465","DOI":"10.2147\/IJN.S336299","article-title":"Targeted PET\/MRI imaging super probes: a critical review of opportunities and challenges","volume":"16","author":"Kastelik-Hryniewiecka","year":"2022","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.arr.2023.101996_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JAD-130485","article-title":"Amyloid-\u03b2 positron emission tomography imaging probes: a critical review","volume":"36","author":"Kepe","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3233\/JAD-190220","article-title":"18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer's disease and mild cognitive impairment evaluation: a global quantitative analysis","volume":"70","author":"Khosravi","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14283\/jpad.2020.68","article-title":"Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab","volume":"8","author":"Klein","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.101996_bib32","unstructured":"Kresge N. 2023. Roche Alzheimer\u2019s Drug Fails in Fresh Blow to Fraught Field [Online]. Bloomberg. Updated 15 November 2022. https:\/\/www.bloomberg.com\/news\/articles\/2022\u201311-14\/roche-says-alzheimer-s-studies-failed-to-meet-primary-endpoints-lagee3f3. (Accessed 5 June 2023)."},{"key":"10.1016\/j.arr.2023.101996_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","article-title":"Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.101996_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/acn3.761","article-title":"Immunotherapy with ponezumab for probable cerebral amyloid angiopathy","volume":"6","author":"Leurent","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.arr.2023.101996_bib35","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1212\/WNL.0000000000005060","article-title":"Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab","volume":"90","author":"Liu","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2023.101996_bib36","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-\u03b2 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2023.101996_bib37","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S2215-0366(21)00197-8","article-title":"The need to show minimum clinically important differences in Alzheimer's disease trials","volume":"8","author":"Liu","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.arr.2023.101996_bib38","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/STROKEAHA.111.636266","article-title":"Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical A\u03b2 deposition","volume":"43","author":"Ly","year":"2012","journal-title":"Stroke"},{"issue":"18","key":"10.1016\/j.arr.2023.101996_bib39","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.101996_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JAD-215046","article-title":"Is amyloid burden measured by 18f-flumetamol pet associated with progression in clinical Alzheimer\u2019s disease?","volume":"85","author":"M\u00fcller","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0166-2236(97)01168-5","article-title":"Alzheimer's disease: a re-examination of the amyloid hypothesis","volume":"21","author":"Neve","year":"1998","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.arr.2023.101996_bib42","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer's disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.101996_bib43","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3233\/JAD-150448","article-title":"Changes in brain volume with bapineuzumab in mild to moderate Alzheimer's disease","volume":"49","author":"Novak","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.101996_bib45","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2023.101996_bib46","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2023.101996_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-200868","article-title":"The role of amyloid-\u03b2 in white matter damage: possible common pathogenetic mechanisms in neurodegenerative and demyelinating diseases","volume":"78","author":"Pietroboni","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib48","unstructured":"Piller, S. 2022. Scientists tie third clinical trial death to experimental Alzheimer\u2019s drug [Online]. Updated 22 December 2022. Scientists tie third clinical trial death to experimental Alzheimer\u2019s drug | Science | AAAS. [Accessed 05.06.2023 2023]."},{"key":"10.1016\/j.arr.2023.101996_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/B978-0-323-85555-6.00019-9","article-title":"Lessons from antiamyloid-\u03b2 immunotherapies in Alzheimer's disease","volume":"193","author":"Plascencia-Villa","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.arr.2023.101996_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.arr.2023.101996_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt7","article-title":"Persistent treatment with cholinesterase inhibitors and\/or memantine slows clinical progression of Alzheimer disease","volume":"1","author":"Rountree","year":"2009","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.101996_bib52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.101996_bib53","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.101996_bib54","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.arr.2023.101996_bib55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.trci.2019.05.007","article-title":"Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease","volume":"5","author":"Schwarz","year":"2019","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.101996_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.arr.2023.101996_bib57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature22809","article-title":"Addendum: the antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"546","author":"Sevigny","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.arr.2023.101996_bib58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.dadm.2018.12.008","article-title":"Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies","volume":"11","author":"Su","year":"2019","journal-title":"Alzheimers Dement (Amst. )"},{"key":"10.1016\/j.arr.2023.101996_bib59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3233\/JAD-190559","volume":"73","author":"Surmak","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101996_bib60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.101996_bib61","unstructured":"U.S. Food and Drug Administration. 2021. FDA Grants Accelerated Approval forAlzheimer\u2019s Drug [Online]. Updated 7 June 2021. FDA Grants Accelerated Approval forAlzheimer\u2019s Drug | FDA. [Accessed 05.06.2023 2023]."},{"key":"10.1016\/j.arr.2023.101996_bib62","article-title":"Disease severity and minimal clinically important differencees in clinical outcome assessments for Alzheimeir\u2019s disease clinical trial","volume":"9","author":"Van Dyck","year":"2023","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.101996_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.101996_bib64","doi-asserted-by":"crossref","first-page":"o3010","DOI":"10.1136\/bmj.o3010","article-title":"Lecanemab for Alzheimer\u2019s disease","volume":"379","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2023.101996_bib65","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/RLU.0000000000004490","article-title":"Re: Aducanumab-related ARIA: paean or lament?","volume":"48","author":"Wassef","year":"2023","journal-title":"Clin. Nucl. Med"},{"key":"10.1016\/j.arr.2023.101996_bib66","article-title":"Integrated Alzheimer's disease rating scale: clinically meaningful change estimates","volume":"8","author":"Wessels","year":"2022","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.101996_bib67","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.1c00062","article-title":"A new highly deuterated [18F]AV-45, [18F]D15FSP, for imaging \u03b2-amyloid plaques in the brain","volume":"12","author":"Xiao","year":"2021","journal-title":"ACS Med Chem. Lett."},{"key":"10.1016\/j.arr.2023.101996_bib68","doi-asserted-by":"crossref","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","article-title":"Long-term effects of cholinesterase inhibitors on cognitive decline and mortality","volume":"96","author":"Xu","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2023.101996_bib69","first-page":"394","article-title":"Amyloids: the history of toxicity and functionality","volume":"10","author":"Yakupova","year":"2021","journal-title":"Biol. (Basel)"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:18:13Z","timestamp":1761592693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163723001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":69,"alternative-id":["S1568163723001551"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2023.101996","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Passive Alzheimer\u2019s immunotherapy: A promising or uncertain option?","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2023.101996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101996"}}